SCM Life Science and T&R Biofab have agreed to collaborate on the research and development of tissue regeneration and therapy products that combine high-purity mesenchymal stem cells with 3D bio-printing technology.
|SCM Life Science CEO Rhee Byung-gun (left) and T&R Biofab CEO Yun Won-soo signed a business partnership contract at the former’s headquarters in Incheon, on Wednesday.|
Under the accord, SCM Life Science plans to combine its high-purity mesenchymal stem cell technology with T&R Biofab’s 3D bioprinting technology and develop tissue regeneration and treatment products to enter the global regenerative medicine market, according to a press release.
The two companies will focus on cell patch products and new formulations for cell therapy and have started verifying the progressiveness, excellence, and safety of their existing therapeutic technologies, it said.
They will do so by using 3D bioprinting technology with improved cell survival rate, bio-ink material suitable for tissue fabrication, good manufacturing practice (GMP)-based cell production system and good laboratory practice (GLP)-based safety evaluation system.
“We are pleased to cooperate with T&R Biofab, a leader in 3D bioprinting technology, to develop new formulations of regenerative medicine with stem cells,” SCM Life Science CEO Rhee Byung-gun said. “With this opportunity, we hope to be able to enter the global market.”
T&R Biofab CEO Yun Won-soo also said, “The company expects that it will be able to accelerate the launch of 3D bioprinting cell therapy products through cooperation with SCM Life Science, which has unique mesenchymal stem cell technology and GMP production facilities.”
<© Korea Biomedical Review, All rights reserved.>